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Background. Rates of Clostridium difficile infection vary widely across Europe, as do prevalent ribotypes. The extent of Europe-
wide diversity within each ribotype, however, is unknown.
Methods. Inpatient diarrheal fecal samples submitted on a single day in summer and winter (2012–2013) to laboratories in 482 
European hospitals were cultured for C. difficile, and isolates the 10 most prevalent ribotypes were whole-genome sequenced. Within 
each ribotype, country-based sequence clustering was assessed using the ratio of the median number of single-nucleotide polymor-
phisms between isolates within versus across different countries, using permutation tests. Time-scaled Bayesian phylogenies were 
used to reconstruct the historical location of each lineage.
Results. Sequenced isolates (n = 624) were from 19 countries. Five ribotypes had within-country clustering: ribotype 356, only 
in Italy; ribotype 018, predominantly in Italy; ribotype 176, with distinct Czech and German clades; ribotype 001/072, including 
distinct German, Slovakian, and Spanish clades; and ribotype 027, with multiple predominantly country-specific clades including in 
Hungary, Italy, Germany, Romania, and Poland. By contrast, we found no within-country clustering for ribotypes 078, 015, 002, 014, 
and 020, consistent with a Europe-wide distribution. Fluoroquinolone resistance was significantly more common in within-country 
clustered ribotypes (P =  .009). Fluoroquinolone-resistant isolates were also more tightly clustered geographically with a median 
(interquartile range) of 43 (0–213) miles between each isolate and the most closely genetically related isolate, versus 421 (204–680) 
miles in nonresistant pairs (P < .001).
Conclusions. Two distinct patterns of C. difficile ribotype spread were observed, consistent with either predominantly health-
care-associated acquisition or Europe-wide dissemination via other routes/sources, for example, the food chain.
Keywords. Clostridium difficile; transmission; healthcare; community; whole genome sequencing.
Clostridium difficile can spread readily in healthcare facilities 
[1] and has caused large-scale healthcare-associated epidemics 
in the 1990s [2] and 2000s [3], particularly with the ribotype 
027/NAP1 strain [4]. However, with enhanced hospital infec-
tion prevention and control [5], <40% of cases are estimated 
to be acquired from other symptomatic cases, using whole-ge-
nome sequencing in Oxford (35%) [6], Leeds (35%) [7], and 
Liverpool (37% of ribotype 027 cases) [8], United Kingdom, 
and 6 hospitals in England (≤31%) [9], and using multilo-
cus variable number tandem repeat analysis in Pennsylvania 
(30%) [10]. Antimicrobial restriction has also probably 
played a key role in reducing C. difficile infection (CDI) [11]. 
For example, CDIs with clindamycin-resistant [12, 13] and 
fluoroquinolone-resistant [14] strains declined in the United 
States and United Kingdom, respectively, after altered antibi-
otic prescribing.
C. difficile is probably also acquired from other sources, includ-
ing patients colonized with toxigenic C. difficile with diarrhea of 
another cause [15] or asymptomatic patients [10, 16–18], asymp-
tomatically colonized children [19, 20], domestic and production 
animals, and the food chain [21]. Strains of C. difficile may have 
particular ecological niches and are preferentially transmitted in 
different environments. For example, ribotype 027/NAP1 has suc-
cessfully spread in healthcare settings worldwide [4]. Ribotype 001/
NAP2 is also found predominantly in hospitals, for example, in the 
United Kingdom [22] and Canada [23]. Ribotype 018 was highly 
transmissible in an Italian hospital study [24], and the closely 
related ribotype 356 was the most common strain in a survey of 
Italian hospitals [25]. In the United States, ribotype 027/NAP1 is 
found in healthcare- and community-associated CDI but still has 
the greatest ratio of healthcare-associated to community-associ-
ated cases among the commonly circulating strains [26].
Other strains have nonhealthcare reservoirs; for example, 
ribotype 078 has been found in pigs and cattle [21, 27] with 
close genetic relatedness on whole-genome sequencing between 
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isolates from pigs, healthy farmers, and CDI case patients in the 
Netherlands [27]. Ribotype 078 infections are more likely to be 
community acquired and affect younger patients [28]. In the 
United States in 2011, ribotype 078/NAP7, ribotype 002/NAP6, 
and to a lesser extent ribotype 020/014/NAP4, occurred pre-
dominantly in community-associated cases, based on surveil-
lance definitions [26]. Community-associated ribotype strains 
may be widely distributed in the environment; for example, 
ribotypes 014, 015, and 078 were all identified at Swiss waste-
water treatment plants [29].
A point-prevalence survey (EUCLID) has demonstrated 
marked Europe-wide variation in both CDI and testing rates 
[30] and prevalent ribotypes [31]. We determined the extent 
of Europe-wide diversity within the 10 most prevalent ribo-
types from that study to investigate whether different modes 
of transmission could plausibly occur across these ribotypes. 
We also investigated the relationship between geographic 
distribution and antimicrobial susceptibilities to explore 
potential drivers of healthcare- and community-associated 
infections.
METHODS
Study Design and Samples
Samples were obtained during a European, multicentre, pro-
spective, point-prevalence study of hospital inpatients with 
diarrhea (EUCLID) [30]. The study included 20 European 
countries, each with a national coordinating laboratory. 
National coordinators selected the 482 participating hospi-
tals to cover all major geographic regions, at a rate of 1 per 
1 million population. Ethical approval was granted in the 
Netherlands, Sweden, and Slovenia; the remaining countries 
did not require such approval because the study was classed 
as surveillance.
All inpatient diarrheal samples submitted to the microbi-
ology laboratory of the participating hospitals on 2 sampling 
days (1 in winter [December 2012 through January 2013], and 
1 in summer [July–August 2013]) were eligible, irrespective 
of the original test(s) requested. Samples were included from 
all patients >2 years old currently occupying a hospital bed, 
including patients in the emergency department but exclud-
ing outpatient clinic attendees. Only 1 sample per patient on 
each sampling day was included. All samples were tested for 
CDI at the national coordinating laboratory using the same 
standardized method (C. DIFF QUIK CHEK COMPLETE; 
Techlab); those that were glutamate dehydrogenase or toxin 
A/B enzyme immunoassay positive were also cultured and 
isolates sent to the Leeds General Infirmary microbiology 
laboratory for polymerase chain reaction ribotyping [32]. 
A total of 7297 inpatient diarrheal samples were tested at 482 
European hospitals [30], resulting in 1211 isolates sent for 
ribotyping, with distribution and characteristics (eg, age) as 
described elsewhere [31].
Sequencing
Isolates from the 10 most prevalent toxigenic ribotypes under-
went whole-genome sequencing. DNA was extracted from 
subculture of a single colony and sequenced using the Illumina 
HiSeq 2500 system. Sequence data were processed as described 
elsewhere [6, 33], mapping reads to the C. difficile 630 reference 
genome (AM180355.1), except for isolates from ribotypes 027 
and 078, whose reads were mapped to CD196 (NC_013315.1) 
and M120 (FN665653.1), respectively. Sequences were com-
pared using single-nucleotide polymorphisms (SNPs), obtain-
ing differences between sequences from maximum likelihood 
phylogenies corrected for recombination [34]. BEAST (version 
2.4.3) [35] and BASTA (version 2.3.0) [36] software were used 
to reconstruct time-scaled phylogenies and to infer the geo-
graphic location of each ancestral lineage. 
A strength of this approach is that it is possible to reconstruct 
past geographic locations and patterns of geographic spread for 
each lineage, despite sequencing isolates at only 2 time points. 
Antimicrobial resistance determinants for fluoroquinolones, 
tetracycline, clindamycin/macrolides, aminoglycosides, and 
fidaxomicin were identified from mapped data and de novo 
assemblies. Further details are provided in the Supplementary 
Methods and Supplementary Table 1. Sequencing quality met-
rics are provided in Supplementary Table  2. Sequence data 
generated are available from the NCBI Sequence Read Archive 
under BioProject PRJNA398458 (see Supplementary Table 3 for 
study sample metadata).
Country-based Clustering
For each ribotype, the median number of SNPs between iso-
lates within a country (SNPwithin), between sequences across 
different countries (SNPacross), and overall were calculated. 
Country-based sequence clustering was assessed using the 
SNPwithin/SNPacross ratio; values closer to 0 indicate greater coun-
try-based clustering. To determine whether observed SNPwithin/
SNPacross ratios were compatible with the null hypothesis of no 
country-based clustering, for each ribotype, the country labels 
of each tip of the phylogenetic tree were permuted 1000 times. 
For each permutation, the ratio was calculated. Country-based 
clustering was supported if the observed ratio was less than the 
2.5% quantile of the distribution of permuted ratios. Because 
both the overall diversity within each ribotype and the num-
ber of samples varied, SNPwithin/SNPacross ratios are not directly 
comparable between ribotypes. A  similar approach was used 
to determine, by ribotype, whether there was evidence of with-
in-hospital clustering in sequences obtained from the same 
country.
RESULTS
Of 1211 isolates obtained in 2012–2013 from 482 European 
hospitals, 678 were from the 10 most prevalent ribotypes 
(Figure 1). Of these, 624 (92%) were retrieved and successfully 
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whole-genome sequenced from ribotypes 027 (n  =  216), 
001/072 (n  =  119), 014 (n =  80), 002 (n  =  44), 018 (n =  34), 
020 (n = 33), 078 (n = 31), 015 (n = 29), 176 (n = 21), and 356 
(n = 17) (Table 1). Sequenced isolates came from 19 countries: 
Germany (n = 268), Italy (n = 72), Poland (n = 56), Hungary 
(n = 46), Romania (n = 36), France (n = 30), United Kingdom 
(n = 29), Czech Republic (n = 20), Slovakia (n = 12), Portugal, 
Spain, Bulgaria, Belgium, Sweden, Ireland, the Netherlands, 
Austria, Finland, and Greece (each n  =  1–10; see Table  2 for 
per-country CDI testing-rate/incidence).
Ribotype Diversity Within and Between Countries
Within ribotypes, the overall median number of SNPs between 
isolates ranged from 9 to 298 (Table 1). Using time-scaled phylog-
enies, the most recent common ancestor for most ribotypes was 
estimated to date from the 18th to the mid-20th century, with the 
exception of ribotypes 176 and 356, which emerged more recently, 
in 1993 (95% highest posterior density interval [HPD], 1977–
2004) and 2008 (2004–2011), respectively. The latter recently 
evolved from ribotype 018 in Italy (Supplementary Figure 1).
Five ribotypes had evidence of clear within-country cluster-
ing: ribotype 356, found only in Italy; ribotype 018, predomi-
nantly isolated in Italy; ribotype 176, with distinct Czech and 
German clades; ribotype 001/072 including distinct German, 
Slovakian, and Spanish clades; and ribotype 027, with mul-
tiple predominantly country-specific clades, including in 
Hungary, Italy, Germany, Romania, and Poland (Figure 2 and 
Supplementary Figures 1–3). For these ribotypes, the SNPwithin/
SNPacross ratio was significantly lower than expected by chance 
(Table 1); for example, for ribotype 027 the ratio was 0.60, ver-
sus an expected value of .93–1.07 without any country-based 
clustering (95% confidence interval from permutation test).
By contrast, there was no evidence of within-country clus-
tering for ribotypes 078, 015, 002, 014, and 020 (Figure 3 and 
Supplementary Figures  4–7), consistent with recent Europe-
wide distribution. For these ribotypes, the SNPwithin/SNPacross 
ratio was approximately 1 and fell within the 95% confidence 
interval expected by chance, assuming no country-based clus-
tering (Table 1).
For most ribotypes the median number of SNPs between 
sequences from the same hospital was less than that between 
sequences within countries—for example, 8 (interquartile range 
[IQR], 3–26) versus 49 (17–71) SNPs for ribotype 027 (Table 3), 
compatible with onward transmission within institutions. For 
ribotypes showing within-country clustering, based on permu-
tation tests, there was evidence of smaller-scale within-institu-
tion clustering for ribotypes 027, 001/072, and 018. There was 
limited local and national diversity within ribotypes 176 and 
356. Among ribotypes compatible with a recent pan-European 
distribution, ribotypes 014, 002, and 015 had lower median 
numbers of within-hospital than within-country SNPs, but 
ribotypes 020 and 078 did not. The median numbers of SNPs 
within countries between pairs of sequences not from the same 
hospital were very similar to those within countries overall, 
demonstrating that, where observed, country-based clustering 
is not just driven by hospital-based clustering.
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Figure 1. Distribution of isolates from sequenced ribotypes by country. Study hospitals were recruited at a rate of 1 per million head of population; hence, differences in 
total isolates obtained between countries represent differences in within-country testing rates and incidence of Clostridium difficile infection (see Table 2).
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy252/4962508
by Institute of Child Health/University College London user
on 28 August 2018
4 • CID 2018:XX (XX XXXX) • Eyre et al
Ta
bl
e 
1.
 
Ex
te
nt
 o
f W
ith
in
-c
ou
nt
ry
 C
lu
st
er
in
g 
by
 R
ib
ot
yp
e
R
ib
ot
yp
e
Is
ol
at
es
, 
N
o.
Is
ol
at
es
 
S
eq
ue
nc
ed
, 
N
o.
 (%
)
C
ou
nt
rie
s 
W
he
re
 
R
ib
ot
yp
e 
W
as
 
Fo
un
d,
 N
o.
 
S
N
P
s 
B
et
w
ee
n 
Is
ol
at
es
,  
O
ve
ra
ll 
M
ed
ia
n 
(IQ
R
) 
TM
R
C
A
  
(9
5%
 H
P
D
)
S
N
P
ac
ro
ss
  
M
ed
ia
n 
 
(IQ
R
) 
S
N
P
w
ith
in
 M
ed
ia
n 
(IQ
R
) 
S
N
P
w
ith
in
/S
N
P
ac
ro
ss
 R
at
io
 
E
xp
ec
te
d 
R
at
io
,  
95
%
 C
Ib
 
C
om
pa
tib
le
 
W
ith
 R
an
do
m
 
E
ur
op
ea
n 
D
is
tr
ib
ut
io
n
D
is
ta
nc
e 
B
et
w
ee
n 
H
os
pi
ta
ls
 fo
r 
M
os
t 
C
lo
se
ly
 R
el
at
ed
 
Is
ol
at
es
, M
ed
ia
n 
(IQ
R
), 
M
ile
sa
02
0
37
33
 (8
9)
9
43
 (3
4–
64
)
19
55
 (1
92
0–
19
86
)
52
 (3
4–
10
4)
42
 (3
4–
60
)
1.
25
.8
4–
1.
24
Ye
s
54
2 
(2
56
–7
96
)
01
4
86
80
 (9
3)
13
14
6 
(6
6–
17
2)
19
63
 (1
92
4–
19
95
)
14
7 
(5
9–
17
3)
14
6 
(6
8–
17
1)
1.
01
.8
7–
1.
09
Ye
s
34
7 
(1
98
–6
08
)
00
2
48
44
 (9
2)
11
73
 (6
1–
97
)
19
55
 (1
92
2–
19
86
)
69
 (5
9–
88
)
75
 (6
2–
10
0)
0.
92
.8
8–
1.
05
Ye
s
44
3 
(1
91
–8
17
)
01
5
30
29
 (9
7)
7
29
8 
(5
4–
36
6)
18
57
 (1
75
7–
19
43
)
29
6 
(2
9–
36
4)
34
6 
(1
89
–4
33
)
0.
86
.8
4–
1.
18
Ye
s
28
0 
(1
76
–5
74
)
07
8
37
31
 (8
4)
9
54
 (3
4–
14
8)
17
21
 (1
55
6–
18
72
)
56
 (2
9–
12
9)
54
 (3
5–
15
2)
1.
04
.7
4–
1.
43
Ye
s
42
4 
(2
66
–8
12
)
02
7
22
3
21
6 
(9
7)
10
71
 (5
0–
11
0)
19
49
 (1
91
3–
19
77
)
49
 (1
7–
71
)
82
 (6
0–
12
5)
0.
60
.9
3–
1.
07
N
o
21
 (0
–1
89
)
00
1/
07
2
13
4
11
9 
(8
9)
14
 2
01
 (4
1–
27
3)
18
51
 (1
75
4–
19
34
)
37
 (2
3–
19
9)
25
3 
(1
73
–3
22
)
0.
15
.7
0–
1.
31
N
o
18
4 
(0
–3
51
)
17
6
25
21
 (8
4)
3
15
 (7
–1
9)
19
93
 (1
97
7–
20
04
)
6 
(4
–8
)
19
 (1
6–
20
)
0.
31
.6
5–
1.
23
N
o
36
 (0
–1
98
)
01
8
36
34
 (9
4)
7
39
 (2
2–
88
)
17
87
 (1
63
8–
19
10
)
28
 (1
7–
38
)
92
 (8
3–
28
5)
0.
30
.4
0–
1.
56
N
o
18
9 
(5
3–
63
6)
35
6
22
17
 (7
7)
1
9 
(5
–1
2)
20
08
 (2
00
4–
20
11
)
9 
(5
–1
2)
…
…
…
N
o
13
3 
(5
7–
24
8)
A
bb
re
vi
at
io
ns
: C
I, 
co
nfi
de
nc
e 
in
te
rv
al
; H
P
D
, h
ig
he
st
 p
os
te
rio
r 
de
ns
ity
 in
te
rv
al
; I
Q
R
, i
nt
er
qu
ar
til
e 
ra
ng
e,
 S
N
P,
 s
in
gl
e-
nu
cl
eo
tid
e 
po
ly
m
or
ph
is
m
; S
N
P
ac
ro
ss
, S
N
P
s 
be
tw
ee
n 
is
ol
at
es
 a
cr
os
s 
di
ffe
re
nt
 c
ou
nt
rie
s;
 S
N
P
w
ith
in
, S
N
P
s 
be
tw
ee
n 
is
ol
at
es
 w
ith
in
 a
 c
ou
nt
ry
; 
TM
R
C
A
, t
im
e 
of
 m
os
t 
re
ce
nt
 c
om
m
on
 a
nc
es
to
r. 
a T
o 
ca
lc
ul
at
e 
th
e 
nu
m
be
r 
of
 m
ile
s 
be
tw
ee
n 
th
e 
m
os
t 
cl
os
el
y 
re
la
te
d 
is
ol
at
es
, w
ith
in
 e
ac
h 
rib
ot
yp
e,
 a
 m
in
im
um
 s
pa
nn
in
g 
tr
ee
 w
as
 c
on
st
ru
ct
ed
 u
si
ng
 S
N
P
 d
is
ta
nc
es
 a
s 
ed
ge
 w
ei
gh
ts
 a
nd
 is
ol
at
es
 a
s 
no
de
s.
 T
he
 p
ro
pe
rt
ie
s 
of
 t
he
 e
dg
es
 (S
N
P
s 
an
d 
m
ile
s)
 o
f 
th
e 
m
in
im
um
-s
pa
nn
in
g 
tr
ee
 w
er
e 
an
al
yz
ed
, s
uc
h 
th
at
 e
ac
h 
is
ol
at
e 
bu
t 
1 
co
nt
rib
ut
es
 1
 d
at
a 
po
in
t 
(s
ee
 F
ig
ur
e 
5)
.
b C
Is
 w
er
e 
ba
se
d 
on
 p
er
m
ut
at
io
n 
te
st
s 
(s
ee
 M
et
ho
ds
).
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy252/4962508
by Institute of Child Health/University College London user
on 28 August 2018
 • CID 2018:XX (XX XXXX) • 5Distinct Patterns of C. difficile Spread
Country-based Clustering and Antimicrobial Resistance
There was a strong association between within-country cluster-
ing and the presence of fluoroquinolone resistance determinants 
(Figure  4). The proportion of isolates with fluoroquinolone 
resistance was significantly higher in the 5 ribotypes showing 
within-country clustering than in the remaining 5 ribotypes 
(rank sum P =  .009). There was no association between clus-
tering and resistance determinants for 3 antimicrobials, tetra-
cyclines (P = .75), aminogylcosides (P = .41), and clindamycin/
macrolides (P  =  .22). No isolates had previously described 
fidaxomicin resistance determinants.
All assessable isolates from ribotypes 027, 176, and 356 
had fluoroquinolone resistance mutations. Only a subset of 
ribotype 018 and 001/072 isolates had resistance mutations 
allowing the date of the most recent common ancestor of each 
resistant clade to be estimated. In ribotype 018, fluoroquino-
lone resistance was estimated to have emerged in 2001 (95% 
HPD, 1993–2008), followed by a clonal expansion restricted 
to Italy, from which ribotype 356 descended (Supplementary 
Figure  1). In ribotype 001/072 fluoroquinolone resistance 
was strongly associated with the presence of ermB, confer-
ring resistance to clindamycin and macrolides. Country-
specific clonal expansions of fluoroquinolone/clindamycin/
macrolide-resistant ribotype 001/072 strains occurred in 
Germany from 2000 (95% HPD, 1992–2007), in Slovakia 
from 2006 (2001–2010), and in Spain from 1994 (1981–2006) 
(Supplementary Figure 2).
Geographic Distance and Genetic Clustering
Ribotypes that clustered by country also showed evidence of 
tighter geographic clustering by region (Figure 5 and Table 1). 
The median geographic distance between each isolate and the 
next most closely genetically related isolate (using minimum 
spanning trees to avoid double counting; see legend to Figure 5) 
was 43 (IQR, 0–213) miles in fluoroquinolone-resistant pairs 
versus 421 (204–680) miles in nonresistant pairs (rank sum 
P  <  .001). By ribotype, the geographic distance between the 
most closely genetically related isolates was lower for fluoro-
quinolone-resistant pairs: 21 (IQR, 0–189), 36 (0–198), and 
133 (57–248) miles in fluoroquinolone-resistant ribotypes 027, 
176 and 356 respectively. In ribotype 001/072, the median dis-
tance was 56 (IQR, 0–221) versus 512 (230–706) miles in flu-
oroquinolone-resistant versus nonresistant pairs, respectively 
(P < .001), and in ribotype 018, it was 160 (53–445) versus 642 
(461–750) miles (P = .08). By contrast, median distances to the 
most genetically related isolates in ribotypes without coun-
try-based clustering were larger, at 443 (IQR, 191–817), 347 
(198–608), 280 (176–564), 542 (256–796), and 424 (266–812) 
miles in ribotypes 002, 014, 015, 020, and 078, respectively.
DISCUSSION
Here we show 2 distinct patterns of C. difficile ribotype spread. 
Ribotypes previously associated with healthcare-based trans-
mission, including ribotypes 027 and 001/072, demonstrated 
evidence of country, regional, and within-hospital clustering. 
This geographic structure was preserved over several years of 
C.  difficile evolution in each ribotype. In many instances the 
most plausible source of all cases of a particular ribotype, or 
subclade of a ribotype, in a country could be explained by a sin-
gle imported case, suggesting that intercountry transmission of 
C. difficile with these ribotypes is unusual.
By contrast, other ribotypes (002, 014, 015, 020, and 
078)  showed no evidence of country-based clustering, and in 
many cases the most closely genetically related strains were 
separated by several hundred miles. This suggests that these 
ribotypes are widely disseminated across Europe, and sustained 
local transmission is less common than with the healthcare-as-
sociated ribotypes described above. It is likely that there is still 
some secondary transmission of these ribotypes within hospi-
tals. Although by sampling on only 2 days 6 months apart this 
study did not fully capture the extent of local transmission, we 
did find evidence of within-hospital clustering in ribotypes 014, 
002, and 015. 
However, the overall pattern observed is consistent with a domi-
nant route of spread other than healthcare. The association of ribo-
types 078 [27] and 014 [37] with pig farming, and previous findings 
Table 2. Mean Measured Clostridium difficile Infection Rate and Testing 
Rate per 10 000 Bed Daysa 
Country
Mean Measured Rate per 10 000 Bed d
CDI Rate Testing Rate 
Austria 7.2 102.0
Belgium 5.4 95.4
Bulgaria 32.2 1.0
Czech Republic 18.9 140.0
Finland 12.6 102.2
France 3.8 38.8
Germany 24.8 137.2
Greece 3.5 56.4
Hungary 17.7 71.7
Ireland 6.1 274.5
Italy 11.9 67.7
The Netherlands 6.1 88.1
Poland 38.9 135.0
Portugal 17.0 72.3
Romania 93.4 35.4
Slovakia 16.9 84.2
Spain 10.4 95.2
Sweden 11.9 71.8
United Kingdom 5.7 115.8
Europe 18.1 93.9
Abbreviation: CDI, Clostridium difficile infection. 
aMean values are averages for winter and summer sampling days.
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of C.  difficile in food, raises the possibility that the food chain 
may be an important vector for these ribotypes. The most recent 
ancestor of pairs of closely related samples from these ribotypes 
was often 5–10 years earlier. Therefore, the spread of these strains 
across Europe may have occurred several years previously with 
persistence in local reservoirs; alternatively, more recent spread 
may have occurred from a reservoir supporting a more diverse 
C. difficile population than that found in a single human host.
We also found that country-based clustering of C.  difficile, 
and therefore probably healthcare-associated transmission, 
was strongly associated with fluoroquinolone resistance, not 
just in ribotype 027 but also in ribotypes 001/072, 018/356, 
and 176. In ribotype 001/072, fluoroquinolone resistance was 
found together with ermB conferring resistance to clindamycin 
and macrolides, possibly reflecting fluoroquinolone resistance 
acquisition by an already successfully healthcare-adapted clin-
damycin-resistant clone or vice versa; otherwise, there was no 
evidence of associations between country-based clustering and 
resistance to other antimicrobials, including tetracycline and 
aminoglycosides. We found no evidence of fidaxomicin resis-
tance. Clostridium difficile is widely resistant to cephalosporins; 
therefore, although cephalosporins can be a risk factor for some 
infections, their use is unlikely to differentially affect the trans-
mission of some ribotypes. 
Supporting the importance of fluoroquinolone use as a 
driver of healthcare-associated CDI, Dingle et al [14] demon-
strated that declining CDI incidence in England this millen-
nium can be accounted for by falls in fluoroquinolone-resistant 
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Figure 2. Ribotype 027 phylogeny with ancestral country reconstruction and antimicrobial resistance determinants. A time-scaled phylogeny, dated in years, is shown with 
the branches colored by the inferred country that the ancestral strains were present in over time. The thickness of the lines indicates the level of posterior support for the 
assigned countries; where the posterior support is <0.8, a numeric value is provided. Note that the choice of inferred ancestor is limited to those sampled. The right-hand 
panel shows for each strain the presence of determinants of tetracycline (tetM, tetO, tetB[P], tet0/32/0, tet40, tetA[P]), clindamycin and macrolide (ermB), aminoglycoside 
(aphA1, AAC[6’]–APH[2’]) and fluoroquinolone (gyrA and gyrB mutations) resistance. Where de novo assemblies or base calls were not of sufficient quality to make reliable 
assignations, the result is denoted as unknown.
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Table 3. Extent of Within-hospital Clustering by Ribotype
Ribotype
SNPs Between Isolates, Median (IQR)
Within-hospital/Different 
Hospital Median SNP Ratio
Expected Ratio, 
95% CIa 
Compatible With 
Hospital-based 
ClusteringWithin Country 
Within 
Hospital 
Within Country, 
Different 
Hospital 
020 52 (34–104) 40 (31–105) 54 (35–104) 0.74 .51–2.04 No
014 147 (59–173) 32 (0–137) 148 (60–173) 0.21 .42–1.17 Yes
002 69 (59–88) 3 (0–21) 69 (60–88) 0.05 .65–1.36 Yes
015 296 (29–364) 2 (0–2) 296 (41–365) 0.01 .14–1.47 Yes
078 56 (29–129) 125 (1–250) 56 (32–128) 2.26 .15–3.86 No
027 49 (17–71) 8 (3–26) 50 (19–71) 0.16 .42–0.56 Yes
001/072 37 (23–199) 9 (4–31) 38 (24–201) 0.23 .70–1.09 Yes
176 6 (4–8) 7 (2–8) 6 (4–8) 1.17 .66–1.17 Limited total diversity
018 28 (17–38) 7 (4–11) 29 (17–38) 0.23 .52–1.38 Yes
356 9 (5–12) 7 (0–7) 9 (5–12) 0.78 .22–1.56 Limited total diversity
Abbreviations: CI, confidence interval; IQR, interquartile range; SNP, single-nucleotide polymorphism.
aCIs were based on permutation tests (see Methods).
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C.  difficile, while levels of fluoroquinolone-susceptible C.  dif-
ficile have remained largely unchanged. Clonal expansions, 
representing rapid successful transmission, followed the acqui-
sition of fluoroquinolone resistance in 2 ribotype 027 lineages 
[4]. Here we provide additional examples of clonal expansions 
following acquisition of fluoroquinolone resistance in ribotypes 
018 and 001/072 dating from the 1990s onward, consistent with 
the launch of fluoroquinolones in Europe in 1987.
In contrast to previous findings of He et al [4], who reported 
frequent and extensive long-range geographic transmission 
within the United Kingdom of ribotype 027, transmission events 
between European countries were relatively rare. They typi-
cally involved geographically adjacent countries, although we 
observed probable spread from the United Kingdom to Poland as 
well, possibly reflecting the population flows between these coun-
tries. We were able to observe marked European country-based 
clustering of some ribotypes because a sufficiently large number 
of isolates was obtained from each country in our study.
A strength of our study is its unbiased sampling of C. difficile 
across Europe, with samples obtained on a single day in sum-
mer and winter, and the number of hospitals from each country 
based on its population. However, because only 2 single time 
points were captured, analyses will tend to underestimate the 
extent of local secondary transmission for all ribotypes, because 
this results in genetically related cases that typically occur close 
in time but are not often sampled on the same day.
Other study limitations include the dependence on the rate 
of submission of diarrheal samples to hospital laboratories. 
Despite efforts to account for some underreporting by testing 
all samples, irrespective of the original test requested, patient 
testing rates varied widely between countries (Table  2). This 
may have affected the relative prevalence of different ribotypes, 
but our conclusions regarding within-country clustering should 
be robust to this. In addition, the reconstruction of the ances-
tral country for each lineage is only an approximation, given 
that, owing to limited sample size, we had to assume the same 
effective bacterial population size in each country, and the same 
rates of exchange of strains between all countries. The study is 
also limited by only considering transmission between coun-
tries as discrete entities. The study was insufficiently powered to 
explore regional transmission, including the impact of referral 
networks, hospital characteristics, and differing patient catch-
ments. These could be investigated in larger national studies, 
as has been done for other healthcare-associated pathogens, for 
example, methicillin-resistant Staphylococcus aureus [38].
Our findings have important implications for C. difficile sur-
veillance and control. Its transmission may be more heteroge-
neous than is usually assumed, with different interventions 
required for predominantly healthcare-associated and commu-
nity-associated lineages. Surveillance programs may need to con-
sider routine use of typing to allow the incidence of commonly 
healthcare-associated strains to be followed independently of 
community-associated strains. Although this is theoretically 
possible with surveillance definitions based on the timing of the 
last healthcare exposure, recent healthcare exposure may merely 
be a marker of exposure to a precipitant of symptoms (eg, antibi-
otics), rather than the location of C. difficile acquisition.
Measures to control healthcare-associated C.  difficile are well 
established. However, it is less clear how to control the spread of 
ribotypes that are widely distributed across Europe. Further stud-
ies are required to better understand potential vectors for trans-
mission, for example, contaminated food or use of animal-based 
fertilizers. In principal, better antimicrobial stewardship should 
reduce the risk of all types of CDI, by reducing patients’ exposure to 
provocative antibiotics. However, because C. difficile antimicrobial 
resistance is associated with country-based clustering, stewardship 
may have a greater effect on healthcare-associated strains. If the 
nonclustered ribotypes are found very widely in the environment, 
prevention of exposure may be particularly challenging, and other 
strategies in addition to antimicrobial stewardship may need to be 
explored to reduce infections, including vaccination or prophylaxis 
during at-risk periods, for example, around healthcare exposures.
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